2′ or 3′ -deoxy and 2′,...

Details 2′ or 3′ -deoxy and 2′,... 2′ or 3′ -deoxy and 2′,...

2003-09-26

2008-10-21

Crane, L. E. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S027140, C536S027100

Reexamination Certificate

active

07439351

ABSTRACT:
Method for the sterospecific preparation of 2′ or 3′ deoxy and 2′,3′-dideoxy-β-L-pentafuranonucleoside compounds. 2′ or 3′ deoxy and 2′,3′-dideoxy-β-L-pentofuranonucleoside compounds are also described. Finally, the invention concerns the use of these compounds, and particularly 2′,3′dideoxy-β-L-fluorocytidine, as drugs, and especially as anti-viral agents.

REFERENCES:
patent: 3116282 (1963-12-01), Hunter et al.
patent: 3553192 (1971-01-01), Gauri et al.
patent: 4000137 (1976-12-01), Dvonoch et al.
patent: 4140761 (1979-02-01), Gerin et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4818538 (1989-04-01), Rideout et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5234913 (1993-08-01), Furman, Jr.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5559101 (1996-09-01), Weis et al.
patent: 5561120 (1996-10-01), Lin et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5587480 (1996-12-01), Belleau et al.
patent: 5627160 (1997-05-01), Lin et al.
patent: 5631239 (1997-05-01), Lin et al.
patent: 5770713 (1998-06-01), Imbach
patent: 5770725 (1998-06-01), Gosselin et al.
patent: 5830881 (1998-11-01), Lin et al.
patent: 5849905 (1998-12-01), Gosselin et al.
patent: 6025335 (2000-02-01), Weis et al.
patent: 0 217 580 (1987-04-01), None
patent: 0 285 884 (1988-10-01), None
patent: 0285884 (1988-10-01), None
patent: 0352248 (1989-07-01), None
patent: 0 337 713 (1989-10-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 375 329 (1990-06-01), None
patent: 0 382 526 (1990-08-01), None
patent: 0 433 898 (1991-06-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 515 156 (1992-11-01), None
patent: 0 515 157 (1992-11-01), None
patent: 0 526 253 (1993-02-01), None
patent: WO 88/07532 (1988-10-01), None
patent: WO 88/08001 (1988-10-01), None
patent: WO 89/02733 (1989-04-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 90/12023 (1990-10-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 91/16920 (1991-11-01), None
patent: WO 91/17159 (1991-11-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 92/00315 (1992-01-01), None
patent: WO 92/06102 (1992-04-01), None
patent: WO 92/08717 (1992-05-01), None
patent: WO 92/08727 (1992-05-01), None
patent: WO 92/10496 (1992-06-01), None
patent: WO 92/10497 (1992-06-01), None
patent: WO 92/14729 (1992-09-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 92/21676 (1992-12-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 93/12128 (1993-06-01), None
patent: WO 93/12131 (1993-06-01), None
patent: WO 93/12132 (1993-06-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 94/04154 (1994-03-01), None
patent: WO 94/05300 (1994-03-01), None
patent: WO 94/09793 (1994-05-01), None
patent: WO 94/14456 (1994-07-01), None
patent: WO 94/14802 (1994-07-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 94/26764 (1994-11-01), None
patent: WO 94/27616 (1994-12-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO 95/07287 (1995-03-01), None
patent: WO 95/11252 (1995-04-01), None
patent: WO 95/20595 (1995-08-01), None
patent: WO 96/15132 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
(R) Périgaud et al., “Potential Antiviral Agents. Sterospecific Synthesis of Purines and Pyrimidines Substituted with Chiral Acyclic Chains by Sugar-Ring Opening of [alpha]-L-Arabinopyranosyl Nucleosides,” J. Chem. Soc., Perkin Transactions 1, 1992(15), 1943-1952 (Aug. 7, 1992); supplied by applicant.
Asseline, et al., “Synthesis and Physicochemical Properties of Oligonucleotides built with either alpha-L or beta-L Nucleotides Units and Covalently Linked to an Acridine Derivative,”Nucleic Acids Res., 19 (15):4067-4074 (1991).
Ayoola, et al., “Progress in the Control of Viral Hepatitis: Memorandum from a WHO Meeting,”Bulletin of the World Health Organization, 66(4):443-455 (1988).
Balzarini, J., “Potent and selective anti-HTLV-III/LAV activity of 2′, 3′-dideoxycytidinene, the 2′,3′-unsaturated derivative of 2′,3′-dideoxycytidine,” et al.,Biochem. Biophys. Res. Comm., 140(2): 735-742 (Oct. 30, 1986).
Beach, J. W., et al., “Synthesis of EnantiomericallyPure (2′R,5′S)-(−)-I-[2 (hydroxymethyl)-oathiolan-5-yl]Cytosine . . . ,”J. Org. Chem., 57:2217-2219 (1992).
Beasley, et al., “Hepatocellular Carcinoma and Hepatitis B Virus,”The Lancet, 1129-1133 (1981).
Belleau, B., et al., “Design and Activity of a Novel Class of Nucleoside Analogs . . . ,”Intl. Conf. on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Boutelje, et al.,Chemical Abstracts, 108:128048 (1987).
Carter et al., “Activities of (−)-carbovir and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro,”Antimicrob. Agents Chemother,, 34(6):1297-1300 (Jun. 1990).
Chang, C., et al., “Production of Hepatitis B Virus in vitro by Transient Expression . . . ,”EMBO J., 6(3):675-680 (1987).
Chang, C.-N., et al., “Deoxycytidine Deaminase-resistant Steroisomer is the Active Form of (+)-2′-3′-Thiacytidine in the Inhibition of Hepatitis B Virus Replication,”J. Biol. Chem., 267(20):13938-13942 (1992).
Chang, C-N., et al., “Biochemical Pharmacology of (+) and (−)-2′,3′-Dideoxy-3′Thioacytidine as Anti-Hepatitis B Virus Agents,”J. Biol. Chem., 267(31):22414-22420 (1992).
Chu, C.K., et al., “An Efficient Total Synthesis of 3′-Azido-3′-Deoxythiymidine (AZT) and 3′-Azido-2′,3′-Dideoxyuridine (AZDDU, CS-87) from D-Mannitol,”Tetrahedron Lett., 29(42):5349-5352 (1988).
Chu, et al., “Structure Activity Relationships of Pyrimide Nucleosides as Antiviral Agents for Human Immunodeficienty Virus Type 1 in Peripheral Blood Mononuclear Cells.”J, Med. Chem., 32:612 (1989).
Chu, et al., “Asymmetric Synthesis of Enantiomerically Pure (−)-(1′R,4′R)-Dioxolane-thymine and Its Anti-HIV Activity,”Tetrahedron Letters, 32(31):3791-3794 (1991).
Chu, et al., “Comparative Activity of 2′,3′-Saturated and Unsaturated Pyrimidine and Purine Nucleosides . . . ,”Biochem. Pharm.37(19):3543-3548 (1988).
Chu, et al., “Enantiomeric Synthesis of (+)-BCH-189[(+)-(2S,5R)-1-(Hydroxymethyl) 1,3-oxathiolane-5-yl]cytosine]from D-Mannose and Its Anti-HIV Activity,”J. Org. Chem., 56:6503-6505 (199

Affiliated with

Also associated with

Rating

2′ or 3′ -deoxy and 2′,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2′ or 3′ -deoxy and 2′,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2′ or 3′ -deoxy and 2′,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4019877